Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cingulate Inc. (CING)
USD4.59
-0.12 (-2.55%)
US NASDAQ Healthcare Biotechnology
Address
1901 West 47th Place 66205
Kansas City, KS, US
Kansas City, KS, US
CEO
Shane J. Schaffer
Website
cingulate.com
IPO
2021-12-08
CIK 1862150 ISIN US17248W3034
Also trades on
NASDAQ Capital Market · CING (USD)
NASDAQ Capital Market · CINGW (USD)
Description
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.59
-0.12 (-2.55%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
573.6K
Beta
-0.92
Float Shares
5.60M
Free Float %
99.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -10.77% | -16.54% | -17.94% | -26.83% | +25.79% | +1.15% | +3.29% | -98.11% | -99.59% | -99.59% | -99.59% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
4.59
Low
11.00
+139.7%
Consensus
11.00
+139.7%
Median
11.00
+139.7%
High
11.00
+139.7%
DCF (Unlevered)
0.05
-98.9%
DCF (Levered)
0.40
-91.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
11.00
+139.7%
|
| All Time | 1 |
11.00
+139.7%
|
Quality scores
Altman Z-Score
-5.75
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+59.5% ★ Q1'26: +8.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-5,828.5% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+42.5% Q1'26: +168.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.45×
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 18.65M (-100.0%)
|
2.39M
1.09M – 4.09M
-87.2% YoY
|
6.50M
2.23M – 12.05M
+171.7% YoY
|
21.01M
9.58M – 35.88M
+223.1% YoY
|
44.12M
20.11M – 75.34M
+110.0% YoY
|
70.43M
32.10M – 120.25M
+59.6% YoY
|
| EBITDA |
-14.89M
|
-19.40M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-15.55M
|
-19.94M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-15.55M
est: -39.34M (+60.5%)
|
-22.45M
est: -20.54M (-9.3%)
|
-12.26M
-16.56M – -7.95M
+40.3% YoY
|
-8.80M
-15.30M – -2.30M
+28.2% YoY
|
-3.36M
-5.84M – -889.9K
+61.8% YoY
|
6.30M
1.84M – 12.09M
+287.3% YoY
|
16.29M
4.77M – 31.28M
+158.6% YoY
|
| SGA |
5.55M
|
10.16M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-10.20
est: -9.44 (-8.1%)
|
-4.13
est: -3.82 (-8.1%)
|
-1.92
-3.05 – -1.46
+49.6% YoY
|
-1.47
-2.82 – -0.42
+23.4% YoY
|
-0.56
-1.08 – -0.16
+62.0% YoY
|
1.16
0.34 – 2.23
+307.1% YoY
|
3.00
0.88 – 5.76
+158.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
10
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Peter J. Werth | 2.84M | 19.90% | 33.1K | — | 33.1K | 3.60M | IN | United States | 2023-09-18 | ↗ |
| 2 | Werth Family Investment Associates LLC | 2.81M | 19.80% | — | — | — | 3.60M | OO | Connecticut | 2023-09-18 | ↗ |
| 3 | Werth Family Investment | 853.0K | 7.50% | — | — | — | 853.0K | OO | Connecticut | 2021-12-20 | ↗ |
| 4 | Shane J. Schaffer | 840.8K | 7.40% | 33.0K | — | 33.0K | 807.8K | IN | United | 2021-12-20 | ↗ |
| 5 | Fountainhead Shrugged, LLC | 807.8K | 4.60% | — | — | — | 807.8K | OO | Kansas | 2023-09-18 | ↗ |
| 6 | Matthew Brams | 650.2K | 5.80% | 650.2K | — | 650.2K | — | IN | (4) Citizenship or Place of Organization | 2022-02-14 | ↗ |
| 7 | 17248W105 | 602.7K | 9.00% | — | 602.7K | — | 602.7K | OO | Cayman Islands | 2021-12-14 | ↗ |
| 8 | Jeff Easton | 282.0K | 9.90% | 282.0K | — | 282.0K | — | IN | United States | 2024-02-09 | ↗ |
| 9 | Lind Global Fund II LP | 282.0K | 9.90% | 282.0K | — | 282.0K | — | PN | Delaware | 2024-02-09 | ↗ |
| 10 | Lind Global Partners II LLC | 282.0K | 9.90% | 282.0K | — | 282.0K | — | OO | Delaware | 2024-02-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 137.4K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 371.7K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 2.7K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 7.3K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 539.20 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.25M | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.7K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.5K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 601.11 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 66.26 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.60
Bullish
Ratio by volume
3.00
Bullish
Buys
13
Sells
5
Shares acquired
96.3K
Shares disposed
14.3K
Cash buys
8.00
Cash sales
—
Net activity
+81,925
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 3,422 | 6.21 | 21.3K | 3 | D | ↗ |
| 2026-03-09 | Silva Raul R. | Officer | A-Award | A | Common Stock | 4,526 | 0.00 | — | 6,473 | D | ↗ |
| 2026-03-09 | Schaffer Shane J. | Director / Officer | A-Award | A | Common Stock | 6,862 | 0.00 | — | 7,035 | D | ↗ |
| 2026-03-09 | Patel Nilay Dahyabhai | Officer | A-Award | A | Common Stock | 5,475 | 0.00 | — | 5,475 | D | ↗ |
| 2026-03-09 | Callahan Jennifer L. | Officer | A-Award | A | Common Stock | 15,329 | 0.00 | — | 20,388 | D | ↗ |
| 2026-03-09 | Brams Matthew | Officer | A-Award | A | Common Stock | 4,526 | 0.00 | — | 9,182 | D | ↗ |
| 2026-02-06 | Werth Peter J. | Director | P-Purchase | A | Common Stock | 19,455 | 5.04 | 98.1K | 117,449 | I | ↗ |
| 2026-02-06 | Schaffer Shane J. | Director / Officer | P-Purchase | A | Common Stock | 6,809 | 5.04 | 34.3K | 10,175 | I | ↗ |
| 2026-02-06 | Callahan Jennifer L. | Officer | P-Purchase | A | Warrant to Purchase Common Stock | 3,891 | 5.04 | 19.6K | 3,891 | D | ↗ |
| 2026-02-06 | Brams Matthew | Officer | P-Purchase | A | Warrant to Purchase Common Stock | 1,556 | 5.04 | 7.8K | 1,556 | D | ↗ |
| 2025-12-31 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 6,625 | 4.34 | 28.8K | 6,625 | D | ↗ |
| 2025-11-03 | Downey Bryan Wade | Officer | A-Award | A | Stock Option (right to Buy) | 30,000 | 3.80 | 114.0K | 30,000 | D | ↗ |
| 2025-09-30 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 7,334 | 3.92 | 28.7K | 7,334 | D | ↗ |
| 2025-07-08 | Patel Nilay Dahyabhai | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-07-07 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 51,500 | 4.42 | 227.6K | 51,500 | D | ↗ |
| 2025-07-07 | Schaffer Shane J. | Director / Officer | A-Award | A | Stock Option (right to Buy) | 199,500 | 4.42 | 881.8K | 199,500 | D | ↗ |
| 2025-07-07 | Myers Laurie | Officer | A-Award | A | Stock Option (right to Buy) | 31,000 | 4.42 | 137.0K | 31,000 | D | ↗ |
| 2025-07-07 | Callahan Jennifer L. | Officer | A-Award | A | Stock Option (right to Buy) | 64,500 | 4.42 | 285.1K | 64,500 | D | ↗ |
| 2025-07-07 | Brams Matthew | Officer | A-Award | A | Stock Option (right to Buy) | 52,500 | 4.42 | 232.1K | 52,500 | D | ↗ |
| 2025-06-30 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 1,000 | 4.07 | 4.1K | 1,000 | D | ↗ |
| 2025-06-20 | Werth Peter J. | Director | A-Award | A | Stock Option (right to Buy) | 15,000 | 4.14 | 62.1K | 15,000 | D | ↗ |
| 2025-06-20 | ROBERTS JOHN A | Director | A-Award | A | Stock Option (right to Buy) | 15,000 | 4.14 | 62.1K | 15,000 | D | ↗ |
| 2025-06-20 | Lawrence Bryan Jay | Director | A-Award | A | Stock Option (right to Buy) | 15,000 | 4.14 | 62.1K | 15,000 | D | ↗ |
| 2025-06-20 | Ervin Jeffrey S | Director | A-Award | A | Stock Option (right to Buy) | 15,000 | 4.14 | 62.1K | 15,000 | D | ↗ |
| 2025-03-31 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 1,000 | 4.30 | 4.3K | 1,000 | D | ↗ |
| 2025-02-18 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 17,630 | 4.32 | 76.2K | 17,630 | D | ↗ |
| 2025-02-18 | Schaffer Shane J. | Director / Officer | A-Award | A | Stock Option (right to Buy) | 70,489 | 4.32 | 304.5K | 70,489 | D | ↗ |
| 2025-02-18 | Myers Laurie | Officer | A-Award | A | Stock Option (right to Buy) | 17,630 | 4.32 | 76.2K | 17,630 | D | ↗ |
| 2025-02-18 | Callahan Jennifer L. | Officer | A-Award | A | Stock Option (right to Buy) | 21,140 | 4.32 | 91.3K | 21,140 | D | ↗ |
| 2025-02-18 | Brams Matthew | Officer | A-Award | A | Stock Option (right to Buy) | 17,630 | 4.32 | 76.2K | 17,630 | D | ↗ |
| 2025-01-17 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 2,748 | 4.76 | 13.1K | 2,748 | D | ↗ |
| 2025-01-17 | Schaffer Shane J. | Director / Officer | A-Award | A | Stock Option (right to Buy) | 27,638 | 4.76 | 131.6K | 27,638 | D | ↗ |
| 2025-01-17 | Myers Laurie | Officer | A-Award | A | Stock Option (right to Buy) | 9,319 | 4.76 | 44.4K | 9,319 | D | ↗ |
| 2025-01-17 | Callahan Jennifer L. | Officer | A-Award | A | Stock Option (right to Buy) | 11,539 | 4.76 | 54.9K | 11,539 | D | ↗ |
| 2025-01-17 | Brams Matthew | Officer | A-Award | A | Stock Option (right to Buy) | 2,748 | 4.76 | 13.1K | 2,748 | D | ↗ |
| 2024-12-31 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 1,000 | 4.93 | 4.9K | 1,000 | D | ↗ |
| 2024-12-31 | Brams Matthew | Officer | A-Award | A | Stock Option (right to Buy) | 1,000 | 4.93 | 4.9K | 1,000 | D | ↗ |
| 2024-09-30 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 1,000 | 5.04 | 5.0K | 1,000 | D | ↗ |
| 2024-09-30 | Brams Matthew | Officer | A-Award | A | Stock Option (right to Buy) | 1,000 | 5.04 | 5.0K | 1,000 | D | ↗ |
| 2024-08-15 | Myers Laurie | Officer | S-Sale | D | Common Stock | 202 | 4.17 | 841.33 | 0 | — | ↗ |
| 2024-06-28 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 1,000 | 0.32 | 320.00 | 1,000 | — | ↗ |
| 2024-06-28 | Brams Matthew | Officer | A-Award | A | Stock Option (right to Buy) | 1,000 | 0.32 | 320.00 | 1,000 | — | ↗ |
| 2024-06-12 | Werth Peter J. | Director / 10% Owner | A-Award | A | Stock Option (right to Buy) | 10,000 | 0.70 | 7.0K | 10,000 | — | ↗ |
| 2024-06-12 | ROBERTS JOHN A | Director | A-Award | A | Stock Option (right to Buy) | 10,000 | 0.70 | 7.0K | 10,000 | — | ↗ |
| 2024-06-12 | Lawrence Bryan Jay | Director | A-Award | A | Stock Option (right to Buy) | 10,000 | 0.70 | 7.0K | 10,000 | — | ↗ |
| 2024-06-12 | Ervin Jeffrey S | Director | A-Award | A | Stock Option (right to Buy) | 10,000 | 0.70 | 7.0K | 10,000 | — | ↗ |
| 2024-06-11 | Werth Peter J. | Director / 10% Owner | A-Award | A | Stock Option (right to Buy) | 6,926 | 1.18 | 8.2K | 6,926 | — | ↗ |
| 2024-06-11 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 63,324 | 1.18 | 74.7K | 63,324 | — | ↗ |
| 2024-06-11 | Schaffer Shane J. | Director / Officer | A-Award | A | Stock Option (right to Buy) | 217,677 | 1.18 | 256.9K | 217,677 | — | ↗ |
| 2024-06-11 | ROBERTS JOHN A | Director | A-Award | A | Stock Option (right to Buy) | 5,000 | 1.18 | 5.9K | 5,000 | — | ↗ |
| 2024-06-11 | Myers Laurie | Officer | A-Award | A | Stock Option (right to Buy) | 98,944 | 1.18 | 116.8K | 98,944 | — | ↗ |
| 2024-06-11 | Lawrence Bryan Jay | Director | A-Award | A | Stock Option (right to Buy) | 5,000 | 1.18 | 5.9K | 5,000 | — | ↗ |
| 2024-06-11 | Ervin Jeffrey S | Director | A-Award | A | Stock Option (right to Buy) | 13,875 | 1.18 | 16.4K | 13,875 | — | ↗ |
| 2024-06-11 | Callahan Jennifer L. | Officer | A-Award | A | Stock Option (right to Buy) | 94,986 | 1.18 | 112.1K | 94,986 | — | ↗ |
| 2024-06-11 | Brams Matthew | Officer | A-Award | A | Stock Option (right to Buy) | 63,324 | 1.18 | 74.7K | 63,324 | — | ↗ |
| 2024-04-11 | Werth Peter J. | Director / 10% Owner | M-Exempt | A | Common Stock | 694,096 | 0.00 | 69.41 | 1,175,925 | — | ↗ |
| 2024-03-29 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 1,000 | 1.10 | 1.1K | 1,000 | — | ↗ |
| 2024-03-29 | Brams Matthew | Officer | A-Award | A | Stock Option (right to Buy) | 1,000 | 1.10 | 1.1K | 1,000 | — | ↗ |
| 2024-03-25 | Werth Peter J. | Director / 10% Owner | J-Other | A | Pre-Funded Warrant (right to buy) | 7,053 | 0.00 | 0.71 | 694,096 | — | ↗ |
| 2024-03-04 | Werth Peter J. | Director | A-Award | A | Stock Option (right to Buy) | 1,824 | 1.18 | 2.2K | 1,824 | — | ↗ |
| 2024-03-04 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 16,676 | 1.18 | 19.7K | 16,676 | — | ↗ |
| 2024-03-04 | Schaffer Shane J. | Director / Officer | A-Award | A | Stock Option (right to Buy) | 57,323 | 1.18 | 67.6K | 57,323 | — | ↗ |
| 2024-03-04 | ROBERTS JOHN A | Director | A-Award | A | Stock Option (right to Buy) | 5,000 | 1.18 | 5.9K | 5,000 | — | ↗ |
| 2024-03-04 | Myers Laurie | Officer | A-Award | A | Stock Option (right to Buy) | 26,056 | 1.18 | 30.7K | 26,056 | — | ↗ |
| 2024-03-04 | Lawrence Bryan Jay | Director | A-Award | A | Stock Option (right to Buy) | 5,000 | 1.18 | 5.9K | 5,000 | — | ↗ |
| 2024-03-04 | Ervin Jeffrey S | Director | A-Award | A | Stock Option (right to Buy) | 5,000 | 1.18 | 5.9K | 5,000 | — | ↗ |
| 2024-03-04 | Callahan Jennifer L. | Officer | A-Award | A | Stock Option (right to Buy) | 25,014 | 1.18 | 29.5K | 25,014 | — | ↗ |
| 2024-03-04 | Brams Matthew | Officer | A-Award | A | Stock Option (right to Buy) | 16,676 | 1.18 | 19.7K | 16,676 | — | ↗ |
| 2024-02-12 | ROBERTS JOHN A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-12 | Lawrence Bryan Jay | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-12 | Ervin Jeffrey S | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-25 | Werth Peter J. | Director / 10% Owner | J-Other | A | Pre-Funded Warrant (right to buy) | 687,043 | 0.00 | 68.70 | 687,043 | — | ↗ |
| 2023-12-29 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 1,000 | 7.65 | 7.7K | 1,000 | — | ↗ |
| 2023-09-29 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 10,000 | 0.71 | 7.1K | 10,000 | — | ↗ |
| 2023-09-15 | Callahan Jennifer L. | Officer | P-Purchase | A | Common Stock | 5,000 | 0.67 | 3.3K | 45,508 | — | ↗ |
| 2023-09-08 | Werth Peter J. | Director / 10% Owner | J-Other | A | Pre-Funded Warrant (right to buy) | 6,838,235 | 0.00 | 683.82 | 6,838,235 | — | ↗ |
| 2023-08-11 | Werth Peter J. | Director | P-Purchase | A | Common Stock | 1,823,155 | 0.55 | 1.00M | 2,798,320 | — | ↗ |
| 2023-08-11 | Werth Family Investment Associates LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,798,320 | — | ↗ |
| 2023-06-30 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 10,000 | 0.93 | 9.3K | 10,000 | — | ↗ |
| 2023-06-15 | Werth Peter J. | Director | A-Award | A | Stock Option (right to Buy) | 15,000 | 0.98 | 14.7K | 15,000 | — | ↗ |
| 2023-06-15 | Medeiros Curtis | Director | A-Award | A | Stock Option (right to Buy) | 15,000 | 0.98 | 14.7K | 15,000 | — | ↗ |
| 2023-06-15 | Gallagher Patrick Joseph | Director | A-Award | A | Stock Option (right to Buy) | 15,000 | 0.98 | 14.7K | 15,000 | — | ↗ |
| 2023-06-15 | GIVENS GREGG WM | Director | A-Award | A | Stock Option (right to Buy) | 15,000 | 0.98 | 14.7K | 15,000 | — | ↗ |
| 2023-06-15 | Applebaum Scott | Director | A-Award | A | Stock Option (right to Buy) | 15,000 | 0.98 | 14.7K | 15,000 | — | ↗ |
| 2023-05-15 | Callahan Jennifer L. | Officer | P-Purchase | A | Common Stock | 2,000 | 1.01 | 2.0K | 40,508 | — | ↗ |
| 2023-05-12 | Callahan Jennifer L. | Officer | P-Purchase | A | Common Stock | 4,000 | 1.08 | 4.3K | 38,508 | — | ↗ |
| 2023-03-31 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 10,000 | 0.99 | 9.9K | 10,000 | — | ↗ |
| 2023-02-28 | VAN HORN LOUIS G | Officer | A-Award | A | Stock Option (right to Buy) | 50,000 | 1.79 | 89.5K | 50,000 | — | ↗ |
| 2023-02-28 | Schaffer Shane J. | Director / Officer | A-Award | A | Stock Option (right to Buy) | 90,000 | 1.79 | 161.1K | 90,000 | — | ↗ |
| 2023-02-28 | Myers Laurie | Officer | A-Award | A | Stock Option (right to Buy) | 40,000 | 1.79 | 71.6K | 40,000 | — | ↗ |
| 2023-02-28 | Gilgallon Craig S. | Officer | A-Award | A | Stock Option (right to Buy) | 40,000 | 1.79 | 71.6K | 40,000 | — | ↗ |
| 2023-02-28 | Callahan Jennifer L. | Officer | A-Award | A | Stock Option (right to Buy) | 20,000 | 1.79 | 35.8K | 20,000 | — | ↗ |
| 2023-02-28 | Brams Matthew | Officer | A-Award | A | Stock Option (right to Buy) | 15,000 | 1.79 | 26.9K | 15,000 | — | ↗ |
| 2022-12-30 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 16,084 | 0.00 | — | 16,084 | — | ↗ |
| 2022-12-16 | Schaffer Shane J. | Officer | P-Purchase | A | Warrant to Purchase Common Stock | 200 | 0.26 | 52.40 | 70,738 | — | ↗ |
| 2022-12-15 | Schaffer Shane J. | Officer | P-Purchase | A | Warrant to Purchase Common Stock | 3,642 | 0.26 | 953.11 | 70,538 | — | ↗ |
| 2022-12-14 | Schaffer Shane J. | Officer | P-Purchase | A | Common Stock | 13,267 | 1.01 | 13.4K | 31,500 | — | ↗ |
| 2022-12-14 | Callahan Jennifer L. | Officer | P-Purchase | A | Common Stock | 7,548 | 0.99 | 7.5K | 34,508 | — | ↗ |
| 2022-12-13 | Werth Peter J. | Director | P-Purchase | A | Common Stock | 28,934 | 0.98 | 28.4K | 975,165 | — | ↗ |
| 2022-12-13 | Schaffer Shane J. | Officer | P-Purchase | A | Warrant to Purchase Common Stock | 396 | 0.26 | 102.68 | 66,896 | — | ↗ |
| 2022-11-29 | Callahan Jennifer L. | Officer | P-Purchase | A | Common Stock | 1,530 | 0.98 | 1.5K | 26,960 | — | ↗ |
| 2022-11-28 | Callahan Jennifer L. | Officer | P-Purchase | A | Common Stock | 3,487 | 0.98 | 3.4K | 25,430 | — | ↗ |
| 2022-11-23 | Myers Laurie | Officer | P-Purchase | A | Common Stock | 1,111 | 0.90 | 999.68 | 48,263 | — | ↗ |
| 2022-11-23 | Gilgallon Craig S. | Officer | P-Purchase | A | Common Stock | 3,575 | 0.84 | 3.0K | 9,550 | — | ↗ |
| 2022-11-22 | GIVENS GREGG WM | Director | P-Purchase | A | Common Stock | 85,000 | 0.88 | 74.9K | 154,318 | — | ↗ |
| 2022-09-30 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 15,032 | 0.00 | — | 15,032 | — | ↗ |
| 2022-09-08 | Callahan Jennifer L. | Officer | P-Purchase | A | Common Stock | 3,500 | 1.50 | 5.2K | 21,943 | — | ↗ |
| 2022-09-06 | Werth Peter J. | Director | P-Purchase | A | Common Stock | 74,500 | 1.52 | 113.2K | 946,231 | — | ↗ |
| 2022-09-01 | Myers Laurie | Officer | G-Gift | D | Common Stock | 200 | 0.00 | — | 47,152 | — | ↗ |
| 2022-08-09 | Applebaum Scott | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-30 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 11,017 | 0.00 | — | 11,017 | — | ↗ |
| 2022-06-01 | Myers Laurie | Officer | P-Purchase | A | Common Stock | 200 | 1.18 | 236.38 | 46,716 | — | ↗ |
| 2022-05-17 | Myers Laurie | Officer | P-Purchase | A | Common Stock | 200 | 1.21 | 241.58 | 46,516 | — | ↗ |
| 2022-05-06 | Medeiros Curtis | Director | S-Sale | D | Common Stock | 17,532 | 1.27 | 22.2K | 0 | — | ↗ |
| 2022-03-17 | Werth Peter J. | Director | P-Purchase | A | Common Stock | 27,000 | 1.79 | 48.3K | 871,731 | — | ↗ |
| 2022-03-16 | Myers Laurie | Officer | P-Purchase | A | Common Stock | 353 | 1.40 | 494.13 | 46,316 | — | ↗ |
| 2022-03-16 | Callahan Jennifer L. | Officer | P-Purchase | A | Warrant to Purchase Common Stock | 16,879 | 0.22 | 3.7K | 18,500 | — | ↗ |
| 2022-03-15 | Schaffer Shane J. | Officer | P-Purchase | A | Warrant to Purchase Common Stock | 50,000 | 0.31 | 15.5K | 66,500 | — | ↗ |
| 2022-03-15 | GIVENS GREGG WM | Director | P-Purchase | A | Common Stock | 4,000 | 1.37 | 5.5K | 10,000 | — | ↗ |
| 2022-03-15 | Callahan Jennifer L. | Officer | P-Purchase | A | Warrant to Purchase Common Stock | 1,500 | 120.00 | 180.0K | 21,030 | — | ↗ |
| 2022-03-14 | VAN HORN LOUIS G | Officer | P-Purchase | A | Common Stock | 15,000 | 1.34 | 20.0K | 15,000 | — | ↗ |
| 2022-03-14 | Medeiros Curtis | Director | P-Purchase | A | Common Stock | 17,532 | 1.41 | 24.8K | 17,532 | — | ↗ |
| 2022-03-14 | Gilgallon Craig S. | Officer | P-Purchase | A | Warrant to Purchase Common Stock | 5,016 | 0.33 | 1.7K | 5,016 | — | ↗ |
| 2022-03-14 | GIVENS GREGG WM | Director | P-Purchase | A | Common Stock | 6,000 | 1.29 | 7.7K | 6,000 | — | ↗ |
| 2022-03-14 | Callahan Jennifer L. | Officer | P-Purchase | A | Warrant to Purchase Common Stock | 1,621 | 0.40 | 652.29 | 1,621 | — | ↗ |
| 2022-02-25 | Werth Peter J. | Director | A-Award | A | Stock Option (right to Buy) | 9,000 | 1.38 | 12.4K | 9,000 | — | ↗ |
| 2022-02-25 | VAN HORN LOUIS G | Officer | A-Award | A | Stock Option (right to Buy) | 30,000 | 1.38 | 41.4K | 30,000 | — | ↗ |
| 2022-02-25 | Silva Raul R. | Officer | A-Award | A | Stock Option (right to Buy) | 6,000 | 1.38 | 8.3K | 6,000 | — | ↗ |
| 2022-02-25 | Schaffer Shane J. | Director / Officer | A-Award | A | Stock Option (right to Buy) | 67,500 | 1.38 | 93.2K | 67,500 | — | ↗ |
| 2022-02-25 | Myers Laurie | Officer | A-Award | A | Stock Option (right to Buy) | 30,000 | 1.38 | 41.4K | 30,000 | — | ↗ |
| 2022-02-25 | Medeiros Curtis | Director | A-Award | A | Stock Option (right to Buy) | 9,000 | 1.38 | 12.4K | 9,000 | — | ↗ |
| 2022-02-25 | Hargroves Thomas Jeffrey | Director | A-Award | A | Stock Option (right to Buy) | 9,000 | 1.38 | 12.4K | 9,000 | — | ↗ |
| 2022-02-25 | Gilgallon Craig S. | Officer | A-Award | A | Stock Option (right to Buy) | 30,000 | 1.38 | 41.4K | 30,000 | — | ↗ |
| 2022-02-25 | Gallagher Patrick Joseph | Director | A-Award | A | Stock Option (right to Buy) | 9,000 | 1.38 | 12.4K | 9,000 | — | ↗ |
| 2022-02-25 | GIVENS GREGG WM | Director | A-Award | A | Stock Option (right to Buy) | 9,000 | 1.38 | 12.4K | 9,000 | — | ↗ |
| 2022-02-25 | Conroy Jeffrey X | Director | A-Award | A | Stock Option (right to Buy) | 9,000 | 1.38 | 12.4K | 9,000 | — | ↗ |
| 2022-02-25 | Callahan Jennifer L. | Officer | A-Award | A | Stock Option (right to Buy) | 10,000 | 1.38 | 13.8K | 10,000 | — | ↗ |
| 2022-02-25 | Brams Matthew | Officer | A-Award | A | Stock Option (right to Buy) | 12,500 | 1.38 | 17.3K | 12,500 | — | ↗ |
| 2021-12-10 | Werth Peter J. | Director | A-Award | A | Warrant to Purchase Common Stock | 8,300 | 6.00 | 49.8K | 8,300 | — | ↗ |
| 2021-12-10 | Werth Family Investment Associates LLC | 10% Owner | — | D | Warrant to Purchase Common Stock | 8,300 | 6.00 | 49.8K | 0 | — | ↗ |
| 2021-12-10 | Schaffer Shane J. | Director / Officer | P-Purchase | A | Common Stock | 16,500 | 6.00 | 99.0K | 16,500 | — | ↗ |
| 2021-12-10 | Hargroves Thomas Jeffrey | Director | P-Purchase | A | Common Stock | 8,300 | 6.00 | 49.8K | 8,300 | — | ↗ |
| 2021-12-10 | GIVENS GREGG WM | Director | A-Award | A | Warrant to Purchase Common Stock | 16,500 | 6.00 | 99.0K | 16,500 | — | ↗ |
| 2021-12-07 | Werth Peter J. | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 836,431 | — | ↗ |
| 2021-12-07 | Werth Family Investment Associates LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 836,431 | — | ↗ |
| 2021-12-07 | VAN HORN LOUIS G | Officer | — | I | Common Stock | 0 | 0.00 | — | 141,606 | — | ↗ |
| 2021-12-07 | Silva Raul R. | Officer | — | D | Common Stock | 0 | 0.00 | — | 467,232 | — | ↗ |
| 2021-12-07 | Schaffer Shane J. | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 807,828 | — | ↗ |
| 2021-12-07 | Myers Laurie | Officer | — | D | Common Stock | 0 | 0.00 | — | 45,963 | — | ↗ |
| 2021-12-07 | Medeiros Curtis | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-07 | Hargroves Thomas Jeffrey | Director | — | I | Common Stock | 0 | 0.00 | — | 37,543 | — | ↗ |
| 2021-12-07 | Gilgallon Craig S. | Officer | A-Award | A | Stock Option (right to Buy) | 67,376 | 6.00 | 404.3K | 67,376 | — | ↗ |
| 2021-12-07 | Gallagher Patrick Joseph | Director | — | D | Common Stock | 0 | 0.00 | — | 68,358 | — | ↗ |
| 2021-12-07 | GIVENS GREGG WM | Director | — | D | Common Stock | 0 | 0.00 | — | 16,818 | — | ↗ |
| 2021-12-07 | Fountainhead Shrugged, LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 807,828 | — | ↗ |
| 2021-12-07 | Conroy Jeffrey X | Director | — | D | Common Stock | 0 | 0.00 | — | 4,949 | — | ↗ |
| 2021-12-07 | Callahan Jennifer L. | Officer | A-Award | A | Stock Option (right to Buy) | 22,459 | 6.00 | 134.8K | 22,459 | — | ↗ |
| 2021-12-07 | Brams Matthew | Officer | — | D | Common Stock | 0 | 0.00 | — | 650,240 | — | ↗ |
Executive team
Top executives
Shares Outstanding
5.61M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Shane J. Schaffer, Chairman and CEO | 319.3K | 251.5K | — | 199.5K | — | — | 770.3K | 25.90% | ↗ |
| 2 | 2024 | Laurie A. Myers EVP and COO | 282.7K | 84.8K | — | 90.7K | — | — | 458.2K | 19.80% | ↗ |
| 3 | 2024 | Jennifer L. Callahan SVP and CFO | 254.0K | 105.0K | — | 87.1K | — | — | 446.1K | 19.52% | ↗ |
| 4 | 2023 | Shane J. Schaffer, Chairman and CEO | 492.0K | — | — | 137.6K | — | — | 629.6K | 21.86% | ↗ |
| 5 | 2023 | Laurie A. Myers EVP and COO | 415.2K | — | — | 61.2K | — | — | 476.3K | 12.84% | ↗ |
| 6 | 2023 | Louis G. Van Horn, Former EVP and CFO | 382.2K | — | — | 76.5K | — | — | 458.7K | 16.67% | ↗ |
| 7 | 2023 | Craig S. Gilgallon Former EVP, GC and Secretary | 385.3K | — | — | 61.2K | — | — | 446.4K | 13.70% | ↗ |
| 8 | 2023 | Matthew N. Brams EVP and CMO | 244.8K | — | — | 22.9K | — | — | 267.7K | 8.57% | ↗ |
| 9 | 2022 | Shane J. Schaffer, Chairman and CEO | 475.0K | 29.7K | — | 78.5K | — | — | 583.2K | 13.46% | ↗ |
| 10 | 2022 | Laurie A. Myers EVP and COO | 400.0K | 25.0K | — | 34.9K | — | — | 459.9K | 7.59% | ↗ |
| 11 | 2022 | Louis G. Van Horn, Former EVP and CFO | 380.0K | 23.8K | — | 34.9K | — | — | 438.6K | 7.95% | ↗ |
| 12 | 2022 | Craig S. Gilgallon EVP, GC and Secretary | 380.0K | 23.8K | — | 34.9K | — | — | 438.6K | 7.95% | ↗ |
| 13 | 2022 | Louis G. Van Horn, EVP and CFO | 380.0K | 23.8K | — | 34.9K | — | — | 438.6K | 7.95% | ↗ |
| 14 | 2022 | Craig S. Gilgallon Former EVP, GC and Secretary | 380.0K | 23.8K | — | 34.9K | — | — | 438.6K | 7.95% | ↗ |
| 15 | 2021 | Shane J. Schaffer, Chairman and CEO | 475.0K | — | 3.0K | 920.8K | — | — | 1.40M | 66.04% | ↗ |
| 16 | 2021 | Laurie A. Myers EVP and COO | 400.0K | — | 3.0K | 345.3K | — | — | 748.3K | 46.55% | ↗ |
| 17 | 2021 | Craig S. Gilgallon EVP, GC and Secretary | 380.0K | — | 3.0K | 345.3K | — | — | 728.3K | 47.82% | ↗ |
| 18 | 2021 | Louis G. Van Horn, EVP and CFO | 380.0K | — | 3.0K | 345.3K | — | — | 728.3K | 47.82% | ↗ |
| 19 | 2020 | Shane J. Schaffer, Chairman and CEO | 275.0K | — | — | — | — | — | 275.0K | 0.00% | ↗ |
| 20 | 2020 | Louis G. Van Horn, EVP and CFO | 238.5K | — | — | — | — | — | 238.5K | 0.00% | ↗ |
| 21 | 2020 | Craig S. Gilgallon EVP, GC and Secretary | 235.0K | — | — | — | — | — | 235.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Shane J. Schaffer | Co-Founder, CEO & Director | 794.4K | — |
| Jennifer L. Callahan | Executive VP, CFO & Secretary | 619.5K | female |
| Nilay Patel | Executive VP, Chief Legal Officer & Chief Compliance Officer | 511.0K | male |
| Matthew N. Brams | Co-Founder, Executive Vice President & Chief Medical Officer | 206.3K | — |
| Downey Bryan Wade | Executive VP & Chief Commercial Officer | — | male |
| Raul R. Silva | Co-Founder, Executive Vice President & Chief Science Officer | — | — |
| Thomas Dalton | Vice President of Investor & Public Relations | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CING
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
